🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT04715802
Active, not recruiting Observational

Options on the Breast Reconstruction Timing and Method After Removal of Polyacrylamide Hydrogel

NCT04715802 · tracked via the Priya Life Science China tracker
Sponsor
First Affiliated Hospital of Zhejiang University
Phase
Observational
Started
2006-10-18
Last updated
2025-05-14

Condition(s) studied

BreastMammaplastyBreast Reconstruction

Investigational drug(s) / intervention(s)

Immediate breast reconstruction with implantdelayed breast reconstruction with implantdelayed breast reconstruction with autologous fat transplantation

Immediate breast reconstruction with implant: Because most fillers are under the mammary gland, it is better to place the prosthesis into the opening under the pectoralis major muscle, which avoids contact between the prosthesis and the residual hydrogel to reduce the chance of infection. If postoperative complications disappear and imaging shows no filler remnants after more than 3-month follow-up, secondary breast augmentation can be planned. For placement of the prosthesis, the plane under the pectoralis major is preferred, which avoids prosthesis contact with the residual hydrogel to thus reduce the chance of infection.

delayed breast reconstruction with implant: The first stage included maximal gel removal and purulent tissue debridement, if necessary. Thereafter, patients were invited for a clinical follow-up and discussion about DBR 3 months later. The latter was offered as a second stage in those opting for it.

delayed breast reconstruction with autologous fat transplantation: Because fat injection after PAAG removal has a high infection risk, it is recommended to be conducted after 3-6 months of follow-up. The advantage of autologous fat transplantation is its ability to repair a variety of breast shape deformities caused by PAAG removal. Fat injections may need to be repeated several times. The interval between injections should be at least 3 months. Usually, the amount of transplanted fat is 150-200 mL/side. A multilayer and multi-tunnel injection method is commonly used.

Study summary

Since polyacrylamide hydrogel (PAAG) was used in cosmetic surgery in 1997, about 30 million women have received PAAG injection for breast augmentation. Although the use of PAAG has been prohibited in most countries due to its myriad complications, a large number of symptomatic patients and asymptomatic patients have continued to seek medical advice. The strategy of repairing secondary breast deformities after PAAG removal has increasingly become a concern for both doctors and patients, but there is no standardized algorithm yet. The purpose of the present study was to perform a retrospective study to compare the safety and effectiveness of different reconstruction timing and method after removing the gel.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: 1. history of PAAG breast injection; 2. appeal to remove the gel; 3. availability of complete medical records; 4. accepting the potential complications of the operation and breast deformity after gel removal. 5. agreeing with medical history data collection, clinical follow-up investigation, and independent Complete the questionnaire. Exclusion Criteria: 1. Patients who had other breast diseases; 2. Patients who failed to follow the standard diagnosis, treatment and follow-up; 3. Lost to follow-up due to various reasons or incomplete medical records; 4. Patients with cognitive disorders such as mental illness, understanding, memory, or orientation, and other serious diseases.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Plastic and Reconstructive Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou Zhejiang

More First Affiliated Hospital of Zhejiang University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04715802 on ClinicalTrials.gov ↗ ← All trials in China